NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · LARGE CAP
Mesoblast Ltd. MESO
10 fiscal years on record · USD · FY2024 reported · SEC filings only
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Growth
USD 17.2M
Revenue, FY2024 · full 10-year series below
Revenue $M
Net income $M
FY2024 · Revenue 17.2 · Net income -102.1
15M30M-50M-100M
2015201820212024
Compound annual growth
Revenue compounded at −11.8% a year over the five years to FY2024.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−594 cents
lost on every revenue dollar
Operating margin
Net margin
FY2024 · Net -593.9%
-500%-1000%
201520192024
ROE
FY2024 · ROE -19.0%
-5%-10%-15%
201520192024
Three returns, three denominators.
Return on equity-19.0%
Return on assets-14.1%
Return on capital employedNot available: we don't have a clean operating profit figure for this period.
Each USD of equity lost 19 cents this year.
The 10-year record
10 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative—not applicable◌not available in our data
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income $B | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ |
| EBITDA $B | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ |
| Income tax $B | 0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.1 |
| Net income $B | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.1 | −0.0 |
| Free cash flow $B | −0.1 | −0.0 | −0.1 | −0.1 | −0.1 | −0.1 | ◌ | ◌ | ◌ | ◌ |
| EPS, diluted $ | −0.08 | −0.09 | −0.11 | −0.13 | −0.16 | −0.15 | −0.18 | −0.08 | −0.19 | −0.01 |
| Dividend / sh $ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ |
| Payout % — not applicable: no dividend | — | — | — | — | — | — | — | — | — | — |
| ROE % | −19.0 | −17.9 | −16.4 | −16.9 | −17.5 | −15.1 | −17.5 | −6.6 | −14.7 | −0.8 |
Slide the table for earlier years. "—" not applicable · "◌" not available in our data.
Provenance
Company facts, as filed
How we verify · 0 failures in 38 reconciliationsAUDITED
Reconciled in 10 of the 10 fiscal years we could check. 18 checks were skipped: the balance sheet is not tagged before 2016. 15 checks were skipped: cost of revenue is not tagged before 2022. Eight checks were skipped: EPS is not tagged before 2015.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated inoutside the United States — SEC code C3
Fiscal year endsJune 30
Data on record since2015